Teladoc, Inc. (NYSE:TDOC) will be announcing its earnings results after the market closes on Wednesday, October 25th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Teladoc has set its Q3 guidance at ($0.58)-($0.56) EPS and its FY17 guidance at ($1.55)-($1.52) EPS.

Teladoc (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $44.60 million during the quarter, compared to the consensus estimate of $44.39 million. Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The company’s revenue was up 68.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.38) earnings per share. On average, analysts expect Teladoc to post $-1.46 EPS for the current fiscal year and $-1.17 EPS for the next fiscal year.

Teladoc, Inc. (NYSE TDOC) opened at 34.00 on Wednesday. Teladoc, Inc. has a 12-month low of $14.00 and a 12-month high of $37.55. The company’s market capitalization is $1.93 billion. The stock has a 50 day moving average of $33.22 and a 200 day moving average of $33.22.

ILLEGAL ACTIVITY WARNING: “Teladoc, Inc. (TDOC) Scheduled to Post Quarterly Earnings on Wednesday” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at

In other news, VP Mark Hirschhorn sold 25,000 shares of Teladoc stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $31.93, for a total transaction of $798,250.00. Following the completion of the sale, the vice president now owns 64,987 shares in the company, valued at approximately $2,075,034.91. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Adam C. Vandervoort sold 53,806 shares of Teladoc stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the sale, the insider now owns 33,008 shares of the company’s stock, valued at approximately $1,020,607.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 108,806 shares of company stock valued at $3,471,732. 4.47% of the stock is owned by corporate insiders.

Several research firms have weighed in on TDOC. KeyCorp restated a “buy” rating and issued a $37.00 price objective on shares of Teladoc in a research report on Sunday, September 17th. Robert W. Baird cut shares of Teladoc from an “outperform” rating to a “neutral” rating and raised their price objective for the company from $14.00 to $36.00 in a research report on Monday, September 18th. Chardan Capital raised their price objective on shares of Teladoc from $30.00 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, June 20th. William Blair restated an “outperform” rating on shares of Teladoc in a research report on Tuesday, June 20th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $42.00 price target (up previously from $34.00) on shares of Teladoc in a research report on Tuesday, June 20th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Teladoc presently has a consensus rating of “Buy” and a consensus price target of $38.00.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Earnings History for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with's FREE daily email newsletter.